reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
Irisin
Irisin is a naturally occurring (the body's own) myokine released from exercising skeletal muscle by cleavage of the membrane protein FNDC5, identified as a molecular link between exercise and metabolic benefits including white-to-beige fat conversion.
Evidence landscape: 3 published studies
0 published items under this slug. The broader irisin/FNDC5 literature exceeds 3,000 studies.
- 3 Other research
Not FDA-approved. Not in clinical development as a therapeutic. Irisin is a naturally occurring (the body's own) hormone released during exercise. No exogenous irisin product has been tested in human clinical trials.
No irisin supplement or therapeutic is commercially available. Recombinant irisin is available for research purposes only. Exercise is the established method for increasing circulating irisin levels.
Irisin is a myokine (muscle-derived hormone) cleaved from the membrane protein FNDC5 during exercise. It converts white fat to metabolically active beige fat through UCP1 upregulation. Initial controversy about whether irisin existed in humans was resolved by quantitative mass spectrometry confirmation.
PSI Assessment
In 2012, Bruce Spiegelman's laboratory at Harvard published a Nature paper identifying a previously unknown hormone released from exercising muscle. Named after Iris, the Greek messenger goddess, irisin was shown to convert white fat (energy storage) into beige fat (energy burning) through UCP1 upregulation. The discovery offered a molecular explanation for a question exercise physiology had struggled to answer: why does exercise improve metabolism in ways that calorie burning alone cannot explain? The initial discovery was followed by controversy when some groups could not detect irisin in human blood. This was resolved by quantitative mass spectrometry, confirming irisin is produced and circulates in humans. The receptor (alphaV/beta5 integrin) was identified in 2018. Subsequent research revealed effects beyond fat browning: irisin crosses the blood-brain barrier, enhances BDNF expression, and promotes bone formation. Whether administering exogenous irisin can replicate any of these exercise benefits remains entirely unproven.
Released from exercising muscle. Converts white fat to metabolically active beige fat. Initial existence controversy resolved by mass spectrometry.
The mechanism begins with exercise-induced PGC-1alpha activation in skeletal muscle, which upregulates FNDC5 expression. The extracellular domain of FNDC5 is cleaved to release irisin into circulation. Irisin binds to alphaV/beta5 integrin receptors on adipocytes, activating ERK and p38 MAPK signaling. This upregulates UCP1 (uncoupling protein 1) expression, converting white adipocytes to beige fat cells with increased thermogenic capacity. UCP1 uncouples the mitochondrial electron transport chain from ATP synthesis, dissipating energy as heat rather than storing it. Beyond fat browning, irisin promotes osteoblast differentiation and bone formation through MAPK signaling. It crosses the blood-brain barrier and enhances BDNF (brain-derived neurotrophic factor) expression, providing a molecular link between exercise and cognitive benefits.
What the evidence supports
Irisin is released from exercising muscle by cleavage of FNDC5, confirmed by quantitative mass spectrometry after initial detection controversy. The white-to-beige fat conversion (browning) through UCP1 upregulation is documented in animal models. Irisin crosses the blood-brain barrier and enhances BDNF expression. Exercise-induced circulating irisin increases are documented in human studies.
What is not yet established
Whether exogenous irisin administration replicates the metabolic benefits of exercise. Controlled interventional trials administering irisin to humans have not been published. Whether the fat browning effect is clinically meaningful in humans. Optimal dosing and delivery for therapeutic use.
Research Evidence
The findings below cover the confirmed exercise biology and the significant gap between the body's own irisin physiology and therapeutic application.
Evidence by condition
Evidence dimensions available for each condition Irisin has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Exercise Mimicry / Metabolism | ||||
| Fat Browning | ||||
| Bone Health | ||||
| Neuroprotection |
Irisin is released from exercising skeletal muscle by cleavage of FNDC5 during PGC-1alpha activation. The existence of circulating irisin in humans was confirmed by quantitative mass spectrometry after initial detection controversy. Exercise increases circulating irisin levels in a dose-dependent manner.
The initial controversy was methodological (antibody-based assays lacked specificity). Mass spectrometry resolution established that irisin is a real circulating factor. The broader irisin/FNDC5 literature exceeds 3,000 studies.
How Irisin Works
Irisin is a 112-amino-acid peptide fragment cleaved from the membrane protein FNDC5 during exercise-induced PGC-1alpha activation in skeletal muscle. It binds alphaV/beta5 integrin receptors on adipocytes and osteoblasts.
When the body exercises, muscles release irisin into the bloodstream. Irisin travels to fat tissue and flips a switch that converts white fat (energy storage) into beige fat (energy burning). This is one reason exercise helps with weight management even beyond the calories burned during the workout itself.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Irisin is cleaved from FNDC5 during exercise-induced PGC-1alpha activation in skeletal muscle. It binds to alphaV/beta5 integrin receptors on adipocytes, activating ERK and p38 MAPK signaling, upregulating UCP1 expression. It also promotes osteoblast differentiation and BDNF expression.
What is Irisin being studied for?
Researchers are studying Irisin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Irisin overall. This means a compound can have human studies for one condition but only animal data for another.
Exercise Mimicry / Metabolism
·Human TrialsIrisin converts white fat to thermogenic beige fat through UCP1 upregulation. Circulating irisin levels increase with exercise in humans, measured by mass spectrometry. The metabolic effects represent a molecular link between exercise and fat metabolism.
Limitations: No human clinical trials with exogenous irisin. Whether administering irisin replicates the metabolic benefits of exercise has not been tested. Assay standardization issues complicated early research.
Fat Browning
·Animal StudiesIrisin induces UCP1 expression in white adipocytes, converting them to thermogenic beige fat cells. This is the core mechanism identified in the original 2012 Nature paper.
Limitations: Fat browning is demonstrated in animal models and human cell culture. Whether it is clinically meaningful in humans (sufficient magnitude to affect body composition) has not been established.
Bone Health
·Animal StudiesIrisin promotes osteoblast differentiation and bone formation through MAPK signaling. Low irisin levels correlate with osteoporosis risk in observational human studies.
Limitations: No human therapeutic trials for osteoporosis. The bone formation data is from animal models.
Neuroprotection
·PreclinicalIrisin crosses the blood-brain barrier and enhances BDNF expression in animal models. This provides a molecular link between exercise and cognitive benefits.
Limitations: Neuroprotective effects are from animal studies (preclinical) only. No human data on irisin-mediated neuroprotection.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. Irisin is a naturally occurring (the body's own) hormone. No exogenous irisin product has entered human trials.
Availability: No irisin supplement or therapeutic is commercially available. Recombinant irisin is available for research only. Exercise is the physiological method for increasing irisin levels.
Class context: Irisin is a naturally occurring (the body's own) myokine. No safety concerns from normal physiological levels. The safety of chronic exogenous irisin administration is unknown.
Irisin is naturally produced by muscles during exercise. There are no known safety concerns from normal physiological irisin levels. Exogenous irisin has not been studied in human clinical trials. The primary open question is efficacy and delivery, not toxicity.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Irisin discussion.
Comparison and Related Research
Irisin sits within the exercise-responsive peptide space and connects to the broader myokine and metabolic peptide field.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The discovery paper for irisin. Identified a previously unknown hormone released from muscle during exercise that acts on white fat cells, converting them to a more metabolically active brown-fat-like state. Named after the Greek messenger goddess Iris, irisin was proposed as a molecular link explaining some of the metabolic benefits of exercise.Bostrom P et al., 2012 in Nature. View on PubMed
- 2.Used highly specific tandem mass spectrometry to definitively confirm that irisin circulates in human blood and that levels increase with exercise. This study addressed earlier skepticism about whether irisin existed in humans, providing quantitative evidence that settled a contentious debate in the field.Jedrychowski MP et al., 2015 in Cell Metab. View on PubMed
- 3.Demonstrated that irisin has direct effects on bone tissue beyond its known role in fat metabolism. Administration of recombinant irisin to mice increased cortical bone mass and strength by stimulating bone-forming osteoblast pathways. This expanded the understanding of irisin as a multi-tissue mediator of exercise benefits.Colaianni G et al., 2015 in Proc Natl Acad Sci U S A. View on PubMed
- 4.Identified a role for irisin in brain health, showing that the exercise-induced hormone rescued synaptic plasticity and memory in mouse models of Alzheimer's disease. Irisin crossed the blood-brain barrier and boosted brain-derived neurotrophic factor (BDNF) expression, providing a molecular mechanism linking physical exercise to cognitive protection.Lourenco MV et al., 2019 in Nat Med. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.